BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 35045653)

  • 21. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
    Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
    Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical Efficacy and Safety of R-CDOP Regimen for Treatment of Newly Treated DLBCL Patients with Adverse Prognostic Factors].
    Yang FL; Shi ML; Wu XF; Qi JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1143-1148. PubMed ID: 31418370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
    Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
    [No Abstract]   [Full Text] [Related]  

  • 26. [The prognostic impact of diabetic mellitus and hyperglycemia during DLBCL treatment on patients with diffuse large B-cell lymphoma].
    Hu Y; Xu YJ; Li MZ; Lan YX; Mao L; Ning QY; Xu W; Yang HL; Zhang YZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):151-157. PubMed ID: 33858047
    [No Abstract]   [Full Text] [Related]  

  • 27. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
    Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.
    Deguchi S; Nakashima K; Muramatsu K; Mitsuya K; Oishi T; Shirata K; Hayashi N; Sugino T; Endo M; Nakasu Y
    J Clin Neurosci; 2019 Nov; 69():43-50. PubMed ID: 31427235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.
    Yuan XG; Huang YR; Yu T; Xu Y; Liang Y; Zhang XH; Sun CR; Zhao XY
    Ann Hematol; 2020 Jan; 99(1):93-104. PubMed ID: 31758262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The possible benefit from total tumour resection in primary diffuse large B-cell lymphoma of central nervous system - a one-decade single-centre experience.
    Jelicic J; Todorovic Balint M; Raicevic S; Ilic R; Stanisavljevic D; Bila J; Antic D; Balint B; Andjelic B; Djurasinovic V; Sretenovic A; Vukovic V; Mihaljevic B
    Br J Neurosurg; 2016; 30(1):80-5. PubMed ID: 26337736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma.
    Chen Y; Chen H; Chen L; Zheng X; Yang X; Zheng Z; Zheng J; Yang T; Liu T; Yang Y; Hu J
    Medicine (Baltimore); 2019 Nov; 98(45):e17827. PubMed ID: 31702637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary central nervous system lymphoma: a profile of 26 cases from Western India.
    Agarwal PA; Menon S; Smruti BK; Singhal BS
    Neurol India; 2009; 57(6):756-63. PubMed ID: 20139505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse.
    Cao XX; Li J; Zhang W; Duan MH; Shen T; Zhou DB
    Ann Hematol; 2014 Jun; 93(6):1001-5. PubMed ID: 24408160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
    Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes.
    Lim T; Kim SJ; Kim K; Lee JI; Lim DH; Lee DJ; Baek KK; Lee HY; Han B; Uhm JE; Ko YH; Kim WS
    Ann Hematol; 2011 Dec; 90(12):1391-8. PubMed ID: 21479535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
    Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S
    Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.